Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-25

FDA Approved: YUPELRI — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for YUPELRI (revefenacin) from Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Yupelri (revefenacin)

Snippet

SUPPL AP for YUPELRI (REVEFENACIN)